Niagen Bioscience (NAGE) Total Current Liabilities (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Total Current Liabilities data on file, last reported at $22.8 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 9.54% year-over-year to $22.8 million in Q1 2026; TTM through Mar 2026 was $22.8 million, a 9.54% increase from a year earlier, with the FY2025 full-year figure at $19.9 million, up 10.98% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $22.8 million, up from $19.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for NAGE reached as high as $22.8 million in Q1 2026 and fell as low as $16.7 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $19.4 million across 5 years, with a median of $19.1 million in 2023.
• Across the five-year window, Total Current Liabilities fell 12.97% in 2024 and gained 28.32% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $17.9 million in 2022, then gained by 15.41% to $20.6 million in 2023, then declined by 12.97% to $17.9 million in 2024, then rose by 10.98% to $19.9 million in 2025, then rose by 14.58% to $22.8 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $22.8 million in Q1 2026, $19.9 million in Q4 2025, and $22.7 million in Q3 2025.